Dalbavancin

Summary

Dalbavancin is a synthetic lipoglycopeptide antibiotic approved for prescription use, administered intravenously. It is primarily indicated for acute bacterial skin and skin structure infections (ABSSSI) and is being investigated for more complex Gram‑positive infections such as bone and joint infections, osteomyelitis, and infective endocarditis, owing to its prolonged half‑life and extensive tissue distribution.

Mechanism of Action

Dalbavancin exerts antimicrobial activity through two complementary mechanisms. First, it binds to the D‑ala‑D‑ala terminus of peptidoglycan precursors, blocking transglycosylation and thus inhibiting bacterial cell‑wall synthesis. Second, it possesses an anchoring component that reinforces its attachment to the cell wall, enhancing potency against Gram‑positive organisms, including Staphylococcus aureus.

What the Research Shows

Pharmacokinetic reviews report that dalbavancin penetrates bone and joint tissues at concentrations exceeding MIC90 values for common pathogens, suggesting suitability for osteomyelitis and septic arthritis, although dedicated clinical trials are lacking. A detailed PK/PD analysis highlights its approximately one‑week half‑life, high protein binding (93%), and dose‑proportional exposure, supporting single‑dose or once‑weekly regimens for ABSSSI. The fAUC/MIC index, with a target 24‑hour value of ≥27.1 for S. aureus, correlates with bacterial killing. Emerging discussions consider dalbavancin as a long‑acting option for prolonged infections such as enterococcal endocarditis, but clinical evidence remains preliminary.

Reported Benefits

Evidence shows dalbavancin achieves bone and joint concentrations above MIC breakpoints for key Gram‑positive pathogens, enabling potential use in osteomyelitis and septic arthritis. Its long half‑life permits infrequent dosing, simplifying outpatient therapy and improving adherence. The drug demonstrates enhanced potency versus earlier glycopeptides and effective activity against resistant Staphylococcus species, as reflected in PK/PD targets for S. aureus.

Limitations of the Evidence

Clinical data beyond skin infections are limited; most bone and joint efficacy conclusions derive from pharmacokinetic measurements rather than outcome trials. Dalbavancin does not penetrate cerebrospinal fluid, restricting use in central nervous system infections. The need for dose adjustment is only defined for severe renal impairment (creatinine clearance <30 mL/min), and safety data for extended use are scarce. Further randomized studies are required to confirm its role in endocarditis and other deep‑site infections.

Safety Considerations

The abstracts do not detail specific adverse events, but note that dose adjustments are recommended only for patients with markedly reduced renal function (creatinine clearance <30 mL/min) not on dialysis. As a highly protein‑bound agent, monitoring for potential drug‑drug interactions may be prudent. Absence of cerebrospinal fluid penetration suggests limited utility for meningitis, and clinicians should be aware of the lack of extensive safety data for prolonged therapy.

How It Is Administered

Dalbavancin is administered exclusively by intravenous infusion. Its pharmacokinetic profile supports single‑dose or once‑weekly dosing schedules, typically delivered as a slow IV push or infusion over a defined period, depending on the clinical protocol.

Routes of Administration

Goals & Uses

• OsteomyelitisAnti InfectiveModerate
• Enable outpatient parenteral antimicrobial therapy (OPAT)Care SettingModerate
• Native and prosthetic valve endocarditis (off-label)Anti InfectiveLow
• Treat acute bacterial skin and skin‑structure infections (ABSSSI)InfectionHigh
• Acute bacterial skin and skin structure infections (ABSSSI)Anti InfectiveHigh
• MRSA infectionsAnti InfectiveHigh
• Outpatient parenteral antibiotic therapy (OPAT)Anti InfectiveModerate

Contraindications

• Severe renal impairment (CrCl <30 mL/min) without dose adjustmentRenalModerate
• Hypersensitivity to dalbavancin or other glycopeptide antibioticsAllergyHigh
• Hypersensitivity to other glycopeptides (e.g., vancomycin)AllergyModerate
• Known hypersensitivity to dalbavancinAllergyHigh

Adverse Effects

• HepatotoxicityHepaticUncommonLiver injury or dysfunction
• Infusion‑related reactions (e.g., flushing, pruritus)VascularCommon
• AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
• Elevated hepatic enzymesHepaticUncommon
• Hypersensitivity/anaphylaxisImmunologicalRare
• HeadacheNeurologicCommonPain in the head or upper neck
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• DiarrheaGastrointestinalCommonLoose or frequent stools
• Infusion-related reactions (Red Man Syndrome)Infusion ReactionUncommon

Drug Interactions

• Nephrotoxic agents (e.g., aminoglycosides, vancomycin)Moderate
• WarfarinLow
• VancomycinLow

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairment (moderate to severe)Organ ImpairmentRelative
• Pediatric patients <6 monthsPediatricRelative
• Pediatrics (<18 years)AgeAbsolute
• Severe hepatic impairmentOrgan ImpairmentRelative
• Renal impairment (CrCl <30 mL/min, not on dialysis)RenalRelative

Regulatory Status

• European UnionApprovedApproved: ABSSSIApproved by EMA; same dosing recommendations as US.
• United StatesApprovedApproved: acute bacterial skin and skin‑structure infectionsApproved under brand Dalvance; dosing options include single 1500 mg dose or two‑dose regimen.
• United KingdomApprovedApproved: ABSSSIAvailable via NHS as Dalvance.

FDA approved in 2014 (brand name Dalvance) for ABSSSI; approved in the EU and other jurisdictions for the same indication.

Evidence & Sources

• Antibiotic penetration into bone and joints: An updated review
  Journal ArticleModerateThabit AK, et al.2019-01-01T00:00:00.000000Z
• Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin
  Journal ArticleModerateMolina KC, et al.2022-01-01T00:00:00.000000Z
• Treatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge
  Journal ArticleModerateHerrera-Hidalgo L, et al.2023-01-01T00:00:00.000000Z

Frequently Asked Questions